单次立体定向放疗对比常规分割放疗治疗前列腺癌骨转移
本回顾性研究纳入201例前列腺癌骨转移患者的249个转移灶,比较单次立体定向放疗(SBRT)与常规分割放疗(CFRT)的疗效。SBRT组以18 Gy或20 Gy单次照射为主,CFRT组以8 Gy单次或20 Gy分5次为主。SBRT显著降低野内失败(IFF),但后续远处失败和生化失败率仍较高。
要点
- SBRT组1年和3年IFF分别为4.5%和12.9%,显著低于CFRT组的34.4%和53.3%。
- SBRT组3年生化失败和远处失败估计分别为88.6%和82.2%,提示需筛选优势人群。
核心结论
- 前列腺癌骨转移采用SBRT可显著降低影像学野内失败,但后续远处失败和生化失败率仍较高。
研究设计与样本
- 单中心回顾性研究,分析201例前列腺癌骨转移患者的249个转移灶(SBRT 191个,CFRT 58个),中位随访2.2年。
主要发现
- CFRT组中位至IFF时间为1.6年,SBRT组未达到(>4.4年)。
- SBRT组3年生化失败和远处失败估计分别为88.6%(95%CI 82.0-92.8)和82.2%(95%CI 74.5-87.6)。
关键数值与推荐
- SBRT处方剂量以18 Gy(45.5%)或20 Gy(46.6%)单次照射为主。
- CFRT方案为8 Gy单次(56.9%)或20 Gy分5次(41.4%)。
- 影像随访最常用11C-胆碱PET/CT(79%)或骨扫描(10%)。
临床怎么用
- 对于前列腺癌骨转移,SBRT可显著改善野内控制,但需注意后续远处失败和生化失败风险较高。
- 选择患者时应综合评估,权衡 aggressive 放疗的获益与后续失败风险。
局限性
- 回顾性研究设计可能存在选择偏倚。
- 样本量有限(249个转移灶),随访时间较短(中位2.2年)。
- SBRT组和CFRT组样本量不均衡(191 vs 58)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aimed to compare outcomes of patients with prostate cancer with bone metastases treated with stereotactic body radiation therapy (SBRT) versus conventionally fractionated radiation therapy (CFRT). METHODS AND MATERIALS: An institutional, retrospective review was conducted of patients with prostate cancer receiving radiation therapy to bone metastases. In-field failure (IFF) was the primary outcome of the study, and distant failure (DF) and biochemical failure (BF) were secondary outcomes. RESULTS: A total of 249 metastases (191 SBRT; 58 CFRT) in 201 patients with a median follow-up of 2.2 years were analyzed. The SBRT prescription dose was predominantly 18 Gy (45.5%) or 20 Gy (46.6%) in a single fraction. CFRT was given either as 8 Gy in 1 fraction (56.9%) or 20 Gy in 5 fractions (41.4%). Imaging follow up was performed most frequently with 11C-choline positron emission tomography/computed tomography (79%) or bone scan (10%). The median time to IFF was 1.6 years for CFRT-treated lesions and not met (>4.4 years) for SBRT. The 1- and 3-year IFF estimates were 34.4% (95% confidence interval [CI], 19.9-46.2) and 53.3% (95% CI, 34.3-66.8) for lesions treated with CFRT compared with 4.5% (95% CI, 1.4-7.5) and 12.9% (95% CI, 6.6-18-8) for those treated with SBRT (P < .01). On multivariate regression, the hazard ratio (HR) for IFF with CFRT compared with SBRT was 6.8 (95% CI, 3.7-12.5; P < .01). There were nonsignificant reduced rates of BF (HR, 1.4; 95% CI, 1.0-2.1; P = .05) and DF (HR, 1.3; 95% CI, 1.0-1.8; P = .08) in patients who received SBRT. The 3-year BF and DF estimates in these patients were 88.6% (95% CI, 82.0-92.8) and 82.2% (95% CI, 74.5-87.6), respectively. CONCLUSIONS: SBRT for the management of prostate cancer bone metastases significantly reduces radiographic IFF. However, the high rate of subsequent DF and BF highlights the challenges in selecting patients who may benefit from aggressive radiation therapy.
引用
- Gao RW, Olivier KR, Park SS, et al. Single-fraction Stereotactic Body Radiation Therapy versus Conventionally Fractionated Radiation Therapy for the Treatment of Prostate Cancer Bone Metastases. Adv Radiat Oncol. 2019. PMID: 31011676. doi:10.1016/j.adro.2019.02.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。